MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1515/jpem-2021-0775

Медицинская библиотека · Journal of pediatric endocrinology & metabolism : JPEM · 2022

Complications of orthopedic treatment in patients diagnosed with X-linked hypophosphatemic rickets.

Paludan Carl Gustaf, Thomsen Kristoffer Koed Vittrup, Rahbek Ole, Kold Søren

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

XLHR in children with a Rickets Severity Score ≥2 can now be treated with the new antibody drug, Burosumab, which prevents bone deformities and increases gait endurance. This study illustrates the extent of complications in the traditional orthopedic treatment of XLHR. The impact of surgery and severity of complications in this patient population has not been systematically assessed before.

METHODS

The search strategy resulted in 215 studies and data were collected from 19 eligible studies and complications were categorized. Four medical charts of patients with XLHR at Aalborg University Hospital were assessed.

RESULTS

One complication occurred on average per surgical procedure for XLHR in the published literature. The 168 reported complications were categorized as follows: Type I (n=79): Complications with minimal intervention required and treatment goal still achieved, Type II (n=41): Complications with substantial change in treatment plan and treatment goal still achieved, Type IIIA (n=23): Complications with failure to achieve treatment goal and no new pathology or permanent sequelae, Type IIIB (n=25): Complications with failure to achieve treatment goal and/or new pathology or permanent sequelae.

CONCLUSIONS

In average, one complication occurred per surgery and the severity of complications were substantial. The treatment goal was not achieved in 28% of surgeries whereof half of them resulted in permanent sequalae or new pathology. Our findings support the use of Burosumab for treatment of the skeletal changes in XLHR as the reported side-effects in Burosumab treatment appear negligible compared to the impact of surgeries and related complications (Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 2019;393:2416-27). However, orthopedic surgery might still be needed for correcting deformities restricting activities of daily living in XLHR patients.

Для цитирования: Paludan Carl Gustaf, Thomsen Kristoffer Koed Vittrup, Rahbek Ole, Kold Søren. Complications of orthopedic treatment in patients diagnosed with X-linked hypophosphatemic rickets.. Journal of pediatric endocrinology & metabolism : JPEM. 2022. DOI: 10.1515/jpem-2021-0775.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.